Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Panelists discuss how optimizing tarlatamab administration requires effective multidisciplinary team collaboration, with oncology, pharmacy, neurology, and nursing coordinating on treatment plans, patient monitoring, and adverse event management to ensure consistent, comprehensive care.
Summary for Physicians:
Optimizing Coordination for Tarlatamab Administration:
- Multidisciplinary Team (MDT) Collaboration:
- Regular communication between oncology, pharmacy, neurology, and nursing to align on treatment plans.
- Shared care protocols to ensure consistency in patient monitoring, especially for immune-related adverse effects.
- Joint decision-making for pretreatment screening and addressing adverse events promptly.
- Pharmacy Role:
- Ensure proper drug handling and dosing protocols are followed.
- Support with timely drug availability and managing potential supply chain issues.
- Neurology Input:
- Monitor for any neurological symptoms (eg, seizures, encephalopathy) and adjust management as needed.
General Approach:
- Establish clear workflows for patient care, from infusion to follow-up, ensuring all team members are aware of each stage of treatment.
Encourage routine MDT meetings to review patient progress and adapt as necessary.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
